
Semaglutide (Injectable)
Medical weight management
Your starting dose
New to this medication? Your provider starts you low and steps you up over time.
All-in monthly price
No membership fee · this is the full price · free shipping · avg 4-week supply
Add in-depth bloodwork
Optional — add a physician-reviewed at-home blood panel to your plan.
Your sex-hormone baseline plus the safety markers that matter on therapy — blood counts, liver and kidney function — from one painless upper-arm device. Matched to your sex (PSA for men; progesterone & FSH for women). No needle, no clinic, physician-reviewed.
This treatment requires licensed provider review and approval. Treatment is not guaranteed. If prescribed, medication is fulfilled by a licensed U.S. pharmacy where permitted by law. Compounded medications are not FDA-approved or FDA-cleared.

Reviewed by Dr. Gene, MD · Board-certified Family Medicine
Every Pepti prescription is reviewed by a licensed U.S. physician before it's dispensed — and only provided if clinically appropriate.
Semaglutide (Injectable)
GLP-1 receptor agonist prescribed for medical weight management under licensed physician supervision. Compounded; not FDA-approved.
About a 4-week supply supply at the standard prescribed dose — your physician confirms exact dosing.
A licensed US physician reviews your intake and prescribes when appropriate.
Compounded fresh at a US pharmacy and shipped cold-chain to your door.
Every order ships free — medication, physician care and refills, one all-in price.
Strength is compounded to the exact dose your physician prescribes and stepped up over time; paired with B6 to ease nausea.
Amounts shown are per unit. Compounded fresh at a US FDA-registered pharmacy.
Every batch independently tested
Every medication batch dispensed through Pepti is independently tested by a qualified third-party laboratory for applicable quality and safety standards before the pharmacy releases it. Batches are tested to the same standard used by 503B outsourcing facilities.
Confirms the finished preparation is free of viable microorganisms.
Screens for endotoxins that can cause fever or inflammatory reactions.
Verifies the labeled concentration of the active peptide is what is in the vial.
Checks the active peptide against impurities and degradation products.
Confirms the peptide in the vial is the correct molecule.
Confirms the solution sits within the range specified for injection.
Checks the finished vial for visible and sub-visible particles.
Confirms the vial seal holds so sterility is maintained through the beyond-use date.
- Lot 100526-SEM-1
Tested 2026-10-07 · Biolink Life Sciences Carolinas
Sterility
Sterile
Endotoxin
<2 EU/mL
Potency
99.2%
- Lot 100526-SEM-2
Tested 2026-10-07 · Biolink Life Sciences Carolinas
Sterility
Sterile
Endotoxin
<2 EU/mL
Potency
98.7%
- Lot 100526-SEM-2.5
Tested 2026-10-07 · Biolink Life Sciences Carolinas
Sterility
Sterile
Endotoxin
<2 EU/mL
Potency
99.2%
How Semaglutide is prescribed.
- Adults with a BMI in the range their physician considers appropriate for GLP-1 therapy
- Patients who have struggled with appetite and weight despite diet and exercise
- People who want physician-managed dose escalation rather than a fixed dose
- Patients already on semaglutide who want to continue at their current dose
Your physician decides whether Semaglutide is appropriate for you after reviewing your intake and labs.
Inject 0.25 mL (25 units) subcutaneously once weekly.
- Licensed physician review of your intake, history, and labs
- Medication compounded to your prescription by a PCAB-accredited, FDA-registered pharmacy
- Every batch independently tested before release
- Sterile syringes and alcohol prep pads for injectables
- Tracked delivery to your door, refills on schedule
- Message your physician anytime; dose changes without an appointment
- Store refrigerated (36–46°F / 2–8°C) at all times, including before first use.
- One vial is your monthly supply. A fresh vial ships every 28 days on your refill schedule, so you're always well inside the beyond-use date on your label.
- Protect from light. Wipe the stopper with an alcohol pad before every draw.
- Dispose of syringes in the sharps container per the included instructions.
A typical course of Semaglutide.
Everything published
about Semaglutide.
How it is described to work, pathway by pathway. What the research shows and what it does not. Where it stands with the FDA, dated and sourced.
Read the referencepeer-reviewed, each verified on PubMed
mechanism, evidence, dosing, safety, FAQ
2026 · checked against fda.gov, not memory
How Semaglutide works, and what the research shows.
Semaglutide is a GLP-1 receptor agonist that mimics the body's natural incretin hormone.
It slows gastric emptying, reduces appetite at the hypothalamic level, and improves insulin sensitivity.
Clinical trials show 15-20% body weight loss over 68 weeks.
The landmark STEP 1 trial randomized 1,961 adults with obesity to weekly subcutaneous semaglutide 2.4 mg vs placebo.
Wilding et al., NEJM 2021After 68 weeks, the semaglutide arm achieved a mean weight loss of 14.9% of body weight compared to 2.4% on placebo.
The SUSTAIN program demonstrated significant HbA1c reduction in type 2 diabetes, and the SELECT trial extended the evidence to cardiovascular outcomes — semaglutide reduced major adverse cardiovascular events by 20% in overweight or obese adults with established cardiovascular disease.
2023Compounded semaglutide uses the identical active pharmaceutical ingredient prepared by FDA-registered 503A pharmacies.
Semaglutide (Injectable) vs. Ozempic / Wegovy
Compounded at an FDA-registered 503A pharmacy. Compounded medications are not FDA-approved.
References
- Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) · New England Journal of Medicine (2021) · PMID 33567185
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) · New England Journal of Medicine (2023) · PMID 37952131
- Wadden TA, Bailey TS, Billings LK, et al.. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3) · JAMA (2021) · PMID 33625476
- Rubino D, Abrahamsson N, Davies M, et al.. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial · JAMA (2021) · PMID 33755728
- Marso SP, Bain SC, Consoli A, et al.. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) · New England Journal of Medicine (2016) · PMID 27633186
- Davies M, Færch L, Jeppesen OK, et al.. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial · The Lancet (2021) · PMID 33667417
- Garvey WT, Batterham RL, Bhatta M, et al.. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial · Nature Medicine (2022) · PMID 36216945
- Rubino DM, Greenway FL, Khalid U, et al.. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial · JAMA (2022) · PMID 35015037
- Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) · New England Journal of Medicine (2025) · PMID 40353578
- Sanyal AJ, Newsome PN, Kliers I, et al.. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE) · New England Journal of Medicine (2025) · PMID 40305708
- Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension · Diabetes Obes Metab (2022) · PMID 35441470
- Batsis JA, Gavras A, Gross DC, Cheever CR, Da Silva BR et al.. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review · Ann Intern Med (2026) · PMID 41996180
- Pasternak B, Wintzell V, Hviid A et al.. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study · BMJ (2024) · PMID 38683947
- Bezin J, Gouverneur A, Pénichon M et al.. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer · Diabetes Care (2023) · PMID 36356111
- Hendershot CS, Bremmer MP, Paladino MB, et al.. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial · JAMA Psychiatry (2025) · PMID 39937469
- Klausen MK, Jensen ME, Møller M, et al.. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial · JCI Insight (2022) · PMID 36066977
- Quddos F, Hubshman Z, Tegge A, et al.. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity · Scientific Reports (2023) · PMID 38017205
- Wang W, Volkow ND, Berger NA, et al.. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population · Nature Communications (2024) · PMID 38806481
- Lähteenvuo M, Tiihonen J, Solismaa A, et al.. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder · JAMA Psychiatry (2025) · PMID 39535805
- Eshraghi R, Ghadimi DJ, Montazerinamin S, et al.. Effects of glucagon-like peptide-1 receptor agonists on alcohol consumption: a systematic review and meta-analysis · EClinicalMedicine (2025) · PMID 41324012
- de Faria Moraes B, André Pedral Diniz Leite G, Silveira IB, et al.. Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption and liver-related outcomes: A systematic review and meta-analysis · Drug and Alcohol Dependence (2025) · PMID 40845737
- Jensen ME, Klausen MK, Bergmann ML, et al.. Blood phosphatidylethanol measurements indicate GLP-1 receptor stimulation causes delayed decreases in alcohol consumption · Alcohol, Clinical and Experimental Research (2025) · PMID 40123107
- Hjerpsted JB, Flint A, Brooks A, et al.. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity · Diabetes, Obesity and Metabolism (2018) · PMID 28941314
- Jensterle M, Ferjan S, Ležaič L, et al.. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity · Diabetes, Obesity and Metabolism (2023) · PMID 36511825
- Dahl K, Brooks A, Almazedi F, et al.. Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes · Diabetes, Obesity and Metabolism (2021) · PMID 33710717
- Wu KL, Chaikomin R, Doran S, et al.. Artificially sweetened versus regular mixers increase gastric emptying and alcohol absorption · The American Journal of Medicine (2006) · PMID 16945619
- Mitchell MC Jr, Teigen EL, Ramchandani VA. Absorption and peak blood alcohol concentration after drinking beer, wine, or spirits · Alcoholism: Clinical and Experimental Research (2014) · PMID 24655007
- Edelbroek MA, Horowitz M, Wishart JM, et al.. Effects of erythromycin on gastric emptying, alcohol absorption and small intestinal transit in normal subjects · Journal of Nuclear Medicine (1993) · PMID 8455074
- Samokhvalov AV, Rehm J, Roerecke M. Alcohol Consumption as a Risk Factor for Acute and Chronic Pancreatitis: A Systematic Review and a Series of Meta-analyses · EBioMedicine (2015) · PMID 26844279
- Legro RS, Dodson WC, Kris-Etherton PM, et al.. Randomized Controlled Trial of Preconception Interventions in Infertile Women With Polycystic Ovary Syndrome · J Clin Endocrinol Metab (2015) · PMID 26401593
- Chen H, Lei X, Yang Z, et al.. Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial · Reprod Biol Endocrinol (2025) · PMID 40713699
- Huang KP, Acosta AA, Ghidewon MY, et al.. Dissociable hindbrain GLP1R circuits for satiety and aversion · Nature (2024) · PMID 38987598
- Kanoski SE, Rupprecht LE, Fortin SM, et al.. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide · Neuropharmacology (2012) · PMID 22227019
- Orsama AL, Mattila E, Ermes M, van Gils M et al.. Weight rhythms: weight increases during weekends and decreases during weekdays · Obes Facts (2014) · PMID 24504358
- Steinberg DM, Bennett GG, Askew S, Tate DF. Weighing every day matters: daily weighing improves weight loss and adoption of weight control behaviors · J Acad Nutr Diet (2015) · PMID 25683820
- Ross R, Neeland IJ, Yamashita S, Shai I et al.. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity · Nat Rev Endocrinol (2020) · PMID 32020062
- Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity · Diabetes Obes Metab (2021) · PMID 33269530
- Tronieri JS, Allison KC, DeRouen K, et al.. Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial · American Journal of Clinical Nutrition (2026) · PMID 42323166
- Frid AH, Kreugel G, Grassi G, Halimi S, et al.. New Insulin Delivery Recommendations · Mayo Clin Proc (2016) · PMID 27594187
- Wang K, Zhang S, Liu C, Chen Y. A meta-analysis and meta-regression on the prevalence of lipohypertrophy in diabetic patients on insulin therapy · Therapie (2021) · PMID 33958198
- Chen L, Xing Q, Li J, Zhou J. Injection Technique Education in Patients with Diabetes Injecting Insulin into Areas of Lipohypertrophy: A Randomized Controlled Trial · Diabetes Ther (2021) · PMID 33570716
- Malgave A, Akbar S, Joseph A, Dande Aishwarya, Peraman R, Malayandi R. Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery · Eur J Pharm Biopharm (2025) · PMID 40490042
- Akbar S, Malgave A, Joseph A, Kumar A, Malayandi R. Thermally Stressed Solid-State Stability of Semaglutide: Understanding the Influence of Temperature on Protein Content, Secondary Structure, Phase Transition, and Chemical Degradation · Pharm Res (2026) · PMID 42086873
- Benet A, Halseth T, Kang J, Kim A, Ackermann R, Srinivasan S, Schwendeman S, Schwendeman A. The Effects of pH and Excipients on Exenatide Stability in Solution · Pharmaceutics (2021) · PMID 34452224
- Kopp KL, Lamberth K, Schelde O, et al.. Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists · Pharmaceutical Research (2026) · PMID 42533250
- Belcourt J, Sapowadia A, White CM, et al.. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown · The Annals of Pharmacotherapy (2026) · PMID 41689811
- Mohan V, Kalra S, Ahluwalia A, et al.. Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications · Cureus (2026) · PMID 42769283
- Perkovic V, Tuttle KR, Rossing P, et al.. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) · New England Journal of Medicine (2024) · PMID 38785209
- Hathaway JT, Shah MP, Hathaway DB, et al.. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide · JAMA Ophthalmology (2024) · PMID 38958939
- He L, Wang J, Ping F, et al.. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials · JAMA Internal Medicine (2022) · PMID 35344001
- Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M.. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss · JAMA (2023) · PMID 37796527
- Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R.. Association of semaglutide with risk of suicidal ideation in a real-world cohort · Nature Medicine (2024) · PMID 38182782
- Guo L, Klonoff DC, Al Sifri SN, Bee YM et al.. Consensus Recommendations on Lipohypertrophy: Insights From an International Panel of Experts · Diabetes Research and Clinical Practice (2026) · PMID 42398590
- Plutzky J, Bogdański P, Colhoun HM et al.. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis · Circulation (2026) · PMID 42610271
- Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel · J Clin Pharmacol (2015) · PMID 25475122
- Lau J, Bloch P, Schäffer L, et al.. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide · Journal of Medicinal Chemistry (2015) · PMID 26308095
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide · Frontiers in Endocrinology (2019) · PMID 31031702
- Wharton S, Calanna S, Davies M, et al.. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss · Diabetes, Obesity and Metabolism (2022) · PMID 34514682
- Wharton S, et al.. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial · The Lancet Diabetes & Endocrinology (2025) · PMID 40961952
- Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery · Nat Rev Drug Discov (2021) · PMID 33536635
- Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions · Bioorg Med Chem (2018) · PMID 28720325
- Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions · Drug Discov Today (2015) · PMID 25450771
- Yang XD, Yang YY. Clinical Pharmacokinetics of Semaglutide: A Systematic Review · Drug Des Devel Ther (2024) · PMID 38952487
- Barenbaum SR, Kumar RB, Aronne LJ. Management of Medication-Induced Weight Gain · Gastroenterology Clinics of North America (2023) · PMID 37919025
- Kumar RB, Aronne LJ. Iatrogenic Obesity · Endocrinology and Metabolism Clinics of North America (2020) · PMID 32418589
- Biondi B. Subclinical Hypothyroidism in Patients with Obesity and Metabolic Syndrome: A Narrative Review · Nutrients (2023) · PMID 38201918
- Murphy C, Koehler K. Energy deficiency impairs resistance training gains in lean mass but not strength: A meta-analysis and meta-regression · Scandinavian Journal of Medicine and Science in Sports (2022) · PMID 34623696
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Important safety information
+
Possible side effects
Do not use if you have
If you experience severe side effects, call 911 or go to your nearest emergency room.
dose-specific vials (Semaglutide): 0.25mg → 1 mg per 1 mL vial (1 mg/mL); 0.5mg → 2 mg per 2 mL vial (1 mg/mL); 1mg → 4 mg per 2 mL vial (2 mg/mL); 1.7mg → 7.5 mg per 3 mL vial (2.5 mg/mL); 2mg → 10 mg per 2 mL vial (5 mg/mL); 2.5mg → 10 mg per 2 mL vial (5 mg/mL)
Frequently asked
about Semaglutide (Injectable).
Ozempic (FDA-approved for diabetes) and Wegovy (FDA-approved for weight loss) are brand-name, FDA-approved products. Compounded semaglutide is prepared by an FDA-registered 503A compounding pharmacy and is not FDA-approved — the FDA does not review compounded drugs for safety, effectiveness, or quality. A licensed physician decides whether compounded therapy is appropriate for you.
GLP-1 receptor agonist prescribed for medical weight management under licensed physician supervision. Compounded; not FDA-approved. Semaglutide is prescription-only at Pepti: a licensed physician reviews your assessment and, if appropriate, prescribes it to be compounded by a state-licensed, FDA-registered pharmacy.
Semaglutide is $99 per month at Pepti. That is all-in: medication, physician review and ongoing care, shipping, and messaging. No membership, consult, or visit fees, and the price is the same in every state.
Semaglutide is commonly prescribed for: Adults with a BMI in the range their physician considers appropriate for GLP-1 therapy; Patients who have struggled with appetite and weight despite diet and exercise; People who want physician-managed dose escalation rather than a fixed dose; Patients already on semaglutide who want to continue at their current dose. Whether it is appropriate for you is decided by the reviewing physician from your history, medications, and labs where required.
Yes. Semaglutide is prescription-only. The free online assessment takes about five minutes, a physician licensed in your state reviews it within 4 hours, and if approved the prescription goes to the pharmacy. If not approved, the medication charge is refunded.
Yes. Semaglutide is one of the medications Pepti requires recent bloodwork for before it is prescribed. Upload a recent lab report from any lab, or order Pepti's at-home panel; the physician reviews the results with your assessment.
34 more questions about Pepti, answered.Show fewer
Semaglutide is a subcutaneous injection into the abdomen or thigh with a small insulin syringe. Your kit ships with sterile syringes and alcohol prep pads, and the exact dose and schedule are printed on the pharmacy label. Dosing videos are in your account.
One vial is your monthly supply at the dose your physician prescribes. A fresh vial ships about every 28 days, and the date moves if your physician changes your dose. Store it as the pharmacy label directs, refrigerated.
Once per fill, $99 each time, when the next vial ships. It renews until you cancel, which you can do anytime from your account with no cancellation fee.
The compounded Semaglutide with sterile syringes and alcohol prep pads, free tracked shipping in an unbranded box with insulated packaging, the physician review, ongoing physician care and dose adjustments, and unlimited messaging.
Reported side effects of Semaglutide are usually mild: nausea (most common, especially first 2 weeks); constipation or diarrhea; fatigue; heartburn; reduced appetite (this is the goal). The physician screens your history, medications, and allergies before prescribing, the medication-specific consent lists the known risks, and you can message your physician about anything you notice. Seek emergency care for severe symptoms.
Response varies by person, goal, and dose, and Semaglutide is prescribed for ongoing use rather than a short trial. Your physician sets expectations at approval, tracks how you respond through your account, and adjusts the dose without an appointment.
Yes, one step at a time. Semaglutide moves up the pharmacy's strength ladder when your physician approves, and you pay the cost difference for the higher strength. It is never doubled.
Yes. Add Semaglutide to a plan with another treatment and both go through one assessment and one physician review, shipping together on one schedule. Each keeps its own catalog price. The physician reviews the combination and can adjust it.
Compounded Semaglutide is not FDA-approved. A brand-name form of the active ingredient is FDA-approved for specific indications; Pepti's version is compounded to your physician's prescription by an FDA-registered 503A pharmacy and prescribed off-label.
Yes, when prescribed by a licensed physician and dispensed by a licensed pharmacy, which is how Pepti provides it in every state it serves. Research-use-only Semaglutide sold without a prescription is labeled not for human use and is a different product.
Semaglutide is a GLP-1 receptor agonist that mimics the body's natural incretin hormone. At Pepti it is prescribed to support appetite control, significant weight loss, blood sugar support, cardiovascular health. Individual response varies, and your physician sets expectations at approval.
Semaglutide is a GLP-1 receptor agonist that mimics the body's natural incretin hormone. It slows gastric emptying, reduces appetite at the hypothalamic level, and improves insulin sensitivity. Clinical trials show 15-20% body weight loss over 68 weeks. Compounded Semaglutide is not FDA-approved; it is prescribed off-label by a licensed physician after reviewing your assessment.
Semaglutide is prescribed for appetite control, significant weight loss, blood sugar support, cardiovascular health. It is commonly requested by adults with a BMI in the range their physician considers appropriate for GLP-1 therapy; patients who have struggled with appetite and weight despite diet and exercise; people who want physician-managed dose escalation rather than a fixed dose; patients already on semaglutide who want to continue at their current dose. Whether it is appropriate for you is the reviewing physician's decision.
Semaglutide is studied for appetite control, significant weight loss, blood sugar support, cardiovascular health. Those are the goals it is prescribed to support at Pepti; results vary by person, dose, and consistency, and no outcome is guaranteed. Your physician tracks how you respond through your account.
The landmark STEP 1 trial (Wilding et al., NEJM 2021) randomized 1,961 adults with obesity to weekly subcutaneous semaglutide 2.4 mg vs placebo. After 68 weeks, the semaglutide arm achieved a mean weight loss of 14.9% of body weight compared to 2.4% on placebo. The SUSTAIN program demonstrated significant HbA1c reduction in type 2 diabetes, and the SELECT trial (2023) extended the evidence to cardiovascular outcomes — semaglutide reduced major adverse cardiovascular events by 20% in overweight or obese adults with established cardiovascular disease. Compounded semaglutide uses the identical active pharmaceutical ingredient prepared by FDA-registered 503A pharmacies. References are listed on this page.
Semaglutide is generally not prescribed with: active cancer or history of cancer (unless approved by oncologist); pregnancy or breastfeeding; severe kidney or liver disease; known allergy to the peptide or excipients; personal or family history of medullary thyroid cancer; multiple endocrine neoplasia syndrome type 2; pancreatitis history. The physician screens for these in your intake, and anything that rules Semaglutide out means it is not prescribed and is refunded.
At Pepti. Complete the free assessment, a physician licensed in your state reviews it within 4 hours, and if appropriate Semaglutide is compounded by a state-licensed, FDA-registered pharmacy and shipped free to your door for $99 per month, all-in. Not prescribed means refunded.
Injectable vial: 1 to 3 mL, sized to your dose, containing compounded to your dose Semaglutide. One vial is your monthly supply at the prescribed dose, and a fresh one ships about every 28 days.
Not currently. Semaglutide ships as a multi-dose vial with sterile syringes and prep pads. The pepti Pen is available for 10 other treatments.
$99 per month covers the compounded Semaglutide, the physician review, ongoing physician care including dose adjustments and refill review, unlimited messaging, and free tracked shipping. There is no membership, consult, visit, or refill fee; the only separate charges are optional at-home lab panels and a physician-approved dose increase billed at pharmacy cost.
Yes. Semaglutide is on Pepti's live catalog, which lists only treatments a partner pharmacy can compound and ship today. If a physician prescribes it, it ships; if it ever cannot be dispensed, the charge is refunded.
Semaglutide ships to 50 states, free and tracked, in insulated unbranded packaging. Eligibility is confirmed during the assessment from your shipping address.
$99 per month at Pepti. That includes the compounded Semaglutide, the physician review and ongoing care, free tracked shipping, and messaging, with no membership, consult, or visit fee. The price is the same in every state and every refill is the same price.
Pepti supplies Semaglutide as a monthly injectable vial with syringes and prep pads included, one vial per month at $99, prescribed by a licensed physician after a free online assessment and shipped free from a state-licensed, FDA-registered pharmacy in insulated packaging.
Yes. Pepti prescribes Semaglutide online in 50 states after a free assessment reviewed by a physician licensed in your state. It is compounded by an FDA-registered pharmacy and shipped free, $99 per month all-in. Not prescribed means refunded.
Yes. At Pepti the entire process is telehealth: a five-minute online assessment, recent bloodwork from any lab or an at-home panel, physician review within 4 hours, then Semaglutide ships from the pharmacy. No clinic visit and no video appointment in most cases. $99 per month, all-in.
Yes, for the real thing. Semaglutide sold without a prescription is research-use-only product labeled not for human use, with no physician, no pharmacy, and no verified testing. Pepti's Semaglutide is physician-prescribed, pharmacy-compounded, batch-tested, and $99 per month including the physician and shipping.
Pepti does, in 50 states, with named board-certified physicians, a state-licensed FDA-registered compounding pharmacy, independent batch testing, and one published all-in price of $99 per month with no membership or consult fee. Refunded if the physician does not prescribe.
It is legal to be prescribed Semaglutide online by a licensed physician and have it dispensed by a licensed pharmacy, which is how Pepti provides it. Buying it as a research chemical without a prescription is a different product and is not for human use. Compounded Semaglutide is not FDA-approved; a brand-name form of the active ingredient is FDA-approved for specific indications.
$99 per month at Pepti, including the medication, the physician, and shipping. Refills are the same price and there is no membership fee.
Yes. Pepti has no clinics: the assessment, physician review, messaging, dose changes, and refills all happen online, and Semaglutide ships free from the pharmacy to your door in 50 states.
Start the free assessment at hellopepti.com, choose Semaglutide, and answer the health questions and upload recent labs or order the at-home panel. A physician licensed in your state reviews it within 4 hours. If approved, Semaglutide ships within 1-3 business days and arrives in 1-3 more; if not, the $99 is refunded.
Yes. Semaglutide is one of the medications Pepti requires recent bloodwork for. Upload a lab report from any lab, or order a Pepti at-home panel from $129; the physician reviews it with your assessment.
Pepti ships Semaglutide to 50 states, free and tracked, refrigerated in insulated packaging, directly from the pharmacy. Delivery is 1-3 business days after the pharmacy compounds it.
Questions people ask
about Semaglutide (Injectable).
- Semaglutide: What It Is, Where to Get It Prescribed, and What It CostsSemaglutide — dose-specific vials (Semaglutide): 0.25mg → 1 mg per 1 mL vial (1 mg/mL). Specification, mechanism, dosing, formats, state availability and how to get it prescribed.
- Is Semaglutide Safe? Side Effects, Warnings and Who Should Not Take ItThe documented safety profile of semaglutide: common gastrointestinal effects, the serious risks worth recognising, the absolute contraindications, and what monitoring looks like.
- Where to Buy Semaglutide Online: Compounded vs Branded, and What to VerifySemaglutide is prescription-only. What it is, how compounded and branded differ, how the online process works, what it costs by dose, and the red flags that matter.
- Semaglutide vs Tirzepatide: Mechanism, Dosing, Side Effects and CostA head-to-head comparison of the two compounded GLP-1 medications: how each works, how they are titrated, what each is chosen for, the side-effect profile, price, and who suits which.
- The Best Peptides for Weight Loss: What Physicians Actually PrescribeWhich peptides are prescribed for weight loss, how compounded GLP-1s differ from every other option, what each costs by dose, and where the adjuncts fall short.
- How Much Do Peptides Cost? Real Monthly Prices and What Drives ThemWhat prescription peptides actually cost per month, why single molecules price differently from four-peptide blends, which costs providers hide behind a low headline, and how to compare.
Read more about Semaglutide (Injectable).
Pairs well with these.

Adipotide (Injectable)
Adipose-targeting peptide
$239

FUSION Blend (BPC-157 / MOTS-c / 5-Amino-1MQ / Tesamorelin)
Metabolic support blend
$279

PHYSIQ Blend (Tesamorelin / Ipamorelin / AOD-9604 / MOTS-c)
Body-composition blend
$289

SHRED Blend (AOD-9604 / CJC-1295 / Ipamorelin / MOTS-c)
Fat-metabolism blend
$279
Ready to start with Semaglutide (Injectable)?
Free assessment. Licensed physicians. Money-back guarantee if not approved.
In your pocket.
Message your medical team, track every order, chart every lab marker. 5.0 on the App Store.
Get the app
PCAB-accredited pharmacies on every order.
Every fulfillment runs through a PCAB-accredited pharmacy.
See the lab results
- Rigorous third-party quality & safety inspections
- Cleanliness and sterile processes
- Proper ingredient sourcing
- Accurate dosing and formulation
- Staff training and procedures
- Accredited by NABP & ACHC